Senior Vice President, Chemical Development and Manufacturing Operations
Ken Kent is Senior Vice President, Chemical Development and Manufacturing Operations, Gilead Sciences. He is responsible for Gilead’s entire drug-substance supply and oversees process R&D functions in Foster City, California and Edmonton, Alberta, Canada, as well as internal and outsourced manufacturing.
He played a critical role leading CDMOs in sourcing ingredients and scaling up production of the remdesivir drug substance, Gilead’s COVID-19 treatment, to speed up and increase production. Mr. Kent has contributed to the development and commercialization of more than 25 approved products while growing his career from developing new synthetic routes as a process chemist to increasing leadership responsibilities in cross-functional roles. He has built and led teams with a reputation for innovation, quality, and safety while also fostering inclusion and career development.
He joined Gilead in 1988. He is a member of the American Chemical Society and has published more than 10 papers and patents on the research he has conducted at Gilead.